Real-World Treatment Data from the Phase 4 STELLAR Trial

Author(s):

Panelists discuss the findings from the STELLAR trial, a phase 4 observational study presented at the European Society for Medical Oncology Congress 2024, which compares the efficacy of lenvatinib and sorafenib as first-line treatments for patients with advanced or unresectable hepatocellular carcinoma.

EP: 1.Current Treatment Landscape – difference between unresectable (uHCC) and metastatic (mHCC)

EP: 2.Treatment Decisions Based on BLCL Stage

EP: 3.Current Treatment in First Line – IO + TKI or IO + IO

EP: 4.Use of monotherapy (IO or TKI) or localized treatment in First Line

EP: 5.EMERALD-1 Study Results

EP: 6.Discussion and Summary

EP: 7.LEAP-012 Study Results

EP: 8.Discussion of LEAP-012 and EMERALD-1 Study Results and Appropriate Sequencing

EP: 9.ImBRAVE 050 Study Results and Discussion Around Who is a High-Risk Patient

EP: 10.Choosing Second-Line Therapies: Considering First Line Therapy Received

EP: 11.Discussion of CELESTIAL Trial and Second-Line Treatment in Japan

EP: 12.CELESTIAL Sub-Group Discussion

EP: 13.Discussion of RESORCE Trial

Now Viewing

EP: 14.Real-World Treatment Data from the Phase 4 STELLAR Trial

EP: 15.Importance of Real-World Data in Supporting Treatment Options

EP: 16.CheckMate 9DW Study Results and Use of Ipiimumab/Nivolumab in First- and Second-Line Treatment

EP: 17.Future Directions for Treating uHCC: Triplet Therapy, Epigenetic Therapy, Cytotoxic Agents, and Antibody-Drug Conjugates (ADCs

Video content above is prompted by the following:

Dr. Chan: Please review the data presented at the European Society for Medical Oncology Congress 2024 on from the STELLAR trial, a pPhase 4 observational study of first-line treatment with lenvatinib or sorafenib for patients with advanced hepatocellular carcinoma (HCC) or unresectable HCC. (Radosavljevic MP. Poster Presentation, 964P).